^
    Back
    Association details:
    Biomarker:TMB-L
    Cancer:Triple Negative Breast Cancer
    Drug:Imfinzi (durvalumab) (PD-L1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2022
    Title:

    Low TMB as predictor for additional benefit from neoadjuvant immune checkpoint inhibition in triple-negative breast cancer

    Published date:
    05/26/2022
    Excerpt:
    Strikingly however, within the low-TMB group (durvalumab: n=47; placebo: n=52) we observed a significantly better DDFS in the durvalumab-chemotherapy combination arm…
    Secondary therapy:
    Chemotherapy
    DOI:
    10.1200/JCO.2022.40.16_suppl.581
    Trial ID:
    GeparNuevo